Roivant Sciences Ltd. (ROIV) Stock
ROIV has an Alpha Score of 44 out of 100 (weak), computed on Nov 8, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 4 trades in ROIV since 2025: 2 purchases and 2 sales, most recently Lisa McClain (sale, Oct 31, 2025). Company insiders reported 0 open-market buys and 21 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
What is ROIV's Alpha Score?
How it works →Alpha Score of 44 reflects weak overall profile with strong momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Roivant Sciences Ltd. (ROIV)?
Most recent: Lisa McClain (sale, Oct 31, 2025); records start Jun 17, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-17 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all ROIV political trades →Are Roivant Sciences Ltd. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 3, 26 | Venker Eric | President & Immunovant CEO | SELL | 200.0K | $7.3M |
| Oct 28, 26 | Venker Eric | President & Immunovant CEO | SELL | 200.0K | $7.3M |
| Oct 20, 26 | Venker Eric | President & Immunovant CEO | SELL | 185.9K | $6.5M |
| Oct 20, 26 | Venker Eric | President & Immunovant CEO | SELL | 14.1K | $501K |
| Oct 1, 26 | Epperly Melissa B, | Director | SELL | 16.9K | $608K |
| Oct 1, 26 | Epperly Melissa B, | Director | SELL | 900 | $33K |
| Sep 30, 26 | Venker Eric | President & Immunovant CEO | SELL | 200.0K | $7.3M |
| Sep 15, 26 | Fitzgerald Meghan | Director | SELL | 4.7K | $187K |
| Sep 15, 26 | Fitzgerald Meghan | Director | SELL | 400 | $16K |
| Sep 15, 26 | Epperly Melissa B, | Director | SELL | 4.3K | $172K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are ROIV's key statistics?
Key statistics as of Nov 6, 2026
How does ROIV's valuation compare with the Healthcare sector?
| Metric | ROIV | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -3534.96% | 3.66% | 168 |
| Return on equity | -6.12% | 3.80% | 191 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 8, 2026). P/E excludes loss-making companies.
ROIV price chart
Powered by TradingViewWhat does Roivant Sciences Ltd. do?
Roivant Sciences Ltd. is an American multinational healthcare company that develops transformative medicines and technologies by creating agile, focused subsidiaries called Vants. These Vants target specific therapeutic areas, including autoimmune diseases through Immunovant, severe autoimmune conditions via Priovant, and pulmonary diseases with Pulmovant. The company applies technology across drug discovery, development, and commercialization to accelerate the delivery of innovative therapies to patients. Roivant Sciences Ltd. maintains a broad pipeline of investigational drugs across multiple areas such as immunology, dermatology, rare diseases, and inflammatory conditions. Notable Vants include Kinevant for rare autoimmune and inflammatory diseases, and health technology units like Datavant for healthcare data sharing and Lokavant for clinical trial optimization. Founded in 2014 and headquartered in New York City with offices in Boston and Basel, Roivant Sciences Ltd. operates as a parent to these specialized entities, aligning incentives for efficient execution in the biopharmaceutical sector.